FATE THERAPEUTICS INC - 8-K Filing
Fate Therapeutics reported first-quarter financial results for Q1 2026 on May 13, 2026, with operating expenses reduced by 20% compared to the same period in 2025 and an extended cash runway into 2028. The company is preparing to initiate its Phase 2 RECLAIM-LN trial for FT819 in lupus nephritis patients during H2 2026, following acceptance into the FDA's CDRP program. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $FATE